IP Library › Granted Patent US 8,680,111

Granted Patent B2

US 8,680,111 · App. 13/786,106 · Granted Mar 25, 2014

Macrocyclic derivatives for the treatment of diseases

Inventors: Simon Bailey (San Diego, CA); Benjamin Joseph Burke (San Diego, CA); Michael Raymond Collins (San Diego, CA); Jingrong Jean Cui (San Diego, CA); Judith Gail Deal (Wildomar, CA); Robert Louis Hoffman (San Marcos, CA); Qinhua Huang (San Diego, CA); Ted William Johnson (Carlsbad, CA); Robert Steven Kania (San Diego, CA); John Charles Kath (La Mesa, CA); Phuong Thi Quy Le (San Diego, CA); Michele Ann McTigue (Encinitas, CA); Cynthia Louise Palmer (La Mesa, CA); Paul Francis Richardson (San Diego, CA); Neal William Sach (San Diego, CA)

Assignee: Pfizer Inc.

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 8,680,111
App. No.: 13/786,106
Granted: Mar 25, 2014
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The invention relates to compounds of formula (Φ) as further defined herein and to the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to the uses thereof. The compounds and salts of the present invention inhibit anaplastic lymphoma kinase (ALK) and/or EML4-ALK and are useful for treating or ameliorating abnormal cell proliferative disorders, such as cancer.

Claims (43)

1. A compound of formula (V)

wherein:

A is a ring selected from C 6 -C 12 aryl and 5-6 membered heteroaryl;

R 1 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 12 aryl, 3-12 membered heteroalicyclic and 5-6 membered heteroaryl, wherein each hydrogen on said C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 12 aryl, 3-12 membered heteroalicyclic and 5-6 membered heteroaryl may be independently optionally substituted by halogen, —OH, —NH 2 , —S(O) t R 9 , —S(O) 2 NR 9 R 10 , —S(O) 2 OR 9 , —NO 2 , —CN, —OR 9 , —C(O)R 9 , —OC(O)R 9 , —NR 9 C(O)R 10 , —C(O)OR 9 , —C(═NR 9 )NR 9 R 10 , —NR 9 C(O)NR 9 R 10 , —NR 9 S(O) 2 R 10 or —C(O)NR 9 R 10 ;

each R 2 is independently selected from the group consisting of halogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 12 aryl, 3-12 membered heteroalicyclic, 5-6 membered heteroaryl, —S(O) t R 7 , —S(O) 2 NR 7 R 8 , —S(O) 2 OR 7 , —NO 2 , —(CR 5 R 6 ) q NR 7 R 8 , —N(CR 5 R 6 )(CR 5 R 6 ) q NR 7 R 8 , —OR 7 , —O(CR 5 R 6 )(CR 5 R 6 ) q OR 7 , —O(CR 5 R 6 )(CR 5 R 6 ) q R 7 , —CN, —C(O)R 7 , —OC(O)R 7 , —O(CR 5 R 6 ) q R 7 , —NR 7 C(O)R 8 , —(CR 5 R 6 ) q C(O)OR 7 , —(CR 5 R 6 ) q NR 7 R 8 , —C(═NR 7 )NR 7 R 8 , —NR 7 C(O)NR 7 R 8 , —NR 7 S(O) 2 R 8 and —(CR 5 R 6 ) q C(O)NR 7 R 8 ; wherein each hydrogen on said C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 12 aryl, 3-12 membered heteroalicyclic, and 5-6 membered heteroaryl may be independently optionally substituted by halogen, —OH, —NH 2 , —S(O) t R 9 , —S(O) 2 NR 9 R 10 , —S(O) 2 OR 9 , —NO 2 , —OR 9 , —CN, —C(O)R 9 , —OC(O)R 9 , —NR 9 C(O)R 10 , —C(O)OR 9 , —C(═NR 9 )NR 9 R 10 , —NR 9 C(O)NR 9 R 10 , —NR 9 S(O) 2 R 10 or —C(O)NR 9 R 10 ;

R 3 and R 4 are each independently selected from hydrogen, C 1 -C 6 alkyl and C 3 -C 6 cycloalkyl, wherein each hydrogen on C 1 -C 6 alkyl and C 3 -C 6 cycloalkyl may be independently optionally substituted by halogen, —OH, —NH 2 , —S(O) t R 9 , —S(O) 2 NR 9 R 10 , —S(O) 2 OR 9 , —NO 2 , —CN, —OR 9 , —C(O)R 9 , —OC(O)R 9 , —NR 9 C(O)R 10 , —C(O)OR 9 , —C(═NR 9 )NR 9 R 10 , —NR 9 C(O)NR 9 R 10 , —NR 9 S(O) 2 R 10 or —C(O)NR 9 R 10 ;

each R 5 and R 6 is independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 12 aryl, 3-12 membered heteroalicyclic, 5-6 membered heteroaryl, —OH, —NH 2 , —S(O) t R 9 , —S(O) 2 NR 9 R 10 , —S(O) 2 OR 9 , —NO 2 , —CN, —OR 9 , —C(O)R 9 , —OC(O)R 9 , —NR 9 C(O)R 10 , —C(O)OR 9 , —C(═NR 9 )NR 9 R 10 , —NR 9 C(O)NR 9 R 10 , —NR 9 S(O) 2 R 10 and —C(O)NR 9 R 10 ; wherein each hydrogen on said C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 12 aryl, 3-12 membered heteroalicyclic, and 5-6 membered heteroaryl may be independently optionally substituted by halogen, —OH, —NH 2 , —S(O) t R 9 , —S(O) 2 NR 9 R 10 , —S(O) 2 OR 9 , —NO 2 , —CN, —OR 9 , —C(O)R 9 , —OC(O)R 9 , —NR 9 C(O)R 10 , —C(O)OR 9 , —C(═NR 9 )NR 9 R 10 , —NR 9 C(O)NR 9 R 10 , —NR 9 S(O) 2 R 10 or —C(O)NR 9 R 10 ;

each R 7 and R 8 is independently selected from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 12 aryl, 3-12 membered heteroalicyclic, and 5-6 membered heteroaryl, wherein each hydrogen on said C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 12 aryl, 3-12 membered heteroalicyclic and 5-6 membered heteroaryl may be independently optionally substituted by halogen, —OH, —NH 2 , —S(O) t R 9 , —S(O) 2 NR 9 R 10 , —S(O) 2 OR 9 , —NO 2 , —OR 9 , —CN, —C(O)R 9 , —OC(O)R 9 , —NR 9 C(O)R 10 , —C(O)OR 9 , —C(═NR 9 )NR 9 R 10 , —NR 9 C(O)NR 9 R 10 , —NR 9 S(O) 2 R 10 or —C(O)NR 9 R 10 ;

each R 9 and R 10 is independently selected from hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 12 aryl, 3-12 membered heteroalicyclic, and 5-6 membered heteroaryl;

p is 0, 1, 2, 3 or 4;

each q is independently 0, 1, 2 or 3;

and

each t is independently 0, 1 or 2;

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein R 1 is selected from the group consisting of hydrogen, C 1 -C 6 alkyl, and C 3 -C 6 cycloalkyl, or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein each R 2 is independently selected from the group consisting of C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, —S(O) t R 7 , —S(O) 2 NR 7 R 8 , —OR 7 , —O(CR 5 R 6 )(CR 5 R 6 ) q OR 7 , —O(CR 5 R 6 )(CR 5 R 6 ) q R 7 and —CN; wherein each hydrogen on said C 1 -C 6 alkyl and C 3 -C 6 cycloalkyl may be independently optionally substituted by halogen, —OH, —NH 2 , —S(O) t R 9 , —S(O) 2 NR 9 R 10 , —S(O) 2 OR 9 , —NO 2 , —OR 9 , —CN, —C(O)R 9 , —OC(O)R 9 , —NR 9 C(O)R 10 , —C(O)OR 9 , —C(═NR 9 )NR 9 R 10 , —NR 9 C(O)NR 9 R 10 , —NR 9 S(O) 2 R 10 and —C(O)NR 9 R 10 , or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein A is a ring selected from the group consisting of phenyl, pyridine, pyrimidine, pyridazine, pyrazine, triazine, pyrazole, imidazole, triazole, tetrazole, thiazole, isothiazole, oxazole and isoxazole, or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein R 3 is methyl and R 4 is hydrogen, or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein R 1 is methyl, or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein A is a pyrazole ring, or a pharmaceutically acceptable salt thereof.

8. The compound of claim 1 , which is (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

10. A compound of formula (XV)

wherein:

A is a ring selected from C 6 -C 12 aryl and 5-6 membered heteroaryl;

R 3 is C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl and R 4 is hydrogen, wherein each hydrogen on C 1 -C 6 alkyl or C 3 -C 6 cycloalkyl may be independently optionally substituted by halogen, —OH, —NH 2 , —S(O) t R 9 , —S(O) 2 NR 9 R 10 , —S(O) 2 OR 9 , —NO 2 , —CN, —OR 9 , —C(O)R 9 , —OC(O)R 9 , —NR 9 C(O)R 10 , —C(O)OR 9 , —C(═NR 9 )NR 9 R 10 , —NR 9 C(O)NR 9 R 10 , —NR 9 S(O) 2 R 10 or —C(O)NR 9 R 10 ;

p is 0, 1, 2, 3 or 4;

each q is independently 0, 1, 2 or 3; and

each t is independently 0, 1 or 2;

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 10 , wherein R 1 is methyl, or a pharmaceutically acceptable salt thereof.

12. The compound of claim 10 , wherein each R 2 is independently selected from the group consisting of C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, —S(O) t R 7 , —S(O) 2 NR 7 R 8 , —OR 7 , —O(CR 5 R 6 )(CR 5 R 6 ) q OR 7 , —O(CR 5 R 6 )(CR 5 R 6 ) q R 7 and —CN, or a pharmaceutically acceptable salt thereof.

13. The compound of claim 10 , wherein A is a pyrazole ring, or a pharmaceutically acceptable salt thereof.

14. The compound of claim 10 , wherein R 3 is methyl, or a pharmaceutically acceptable salt thereof.

15. The compound of claim 10 , which is (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition comprising a compound of claim 10 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

17. A compound which is (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition comprising a compound of claim 17 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

Assignments (1)

ASSIGNEE ADDRESS CORRECTION Recorded Mar 20, 2023

From: PFIZER INC.

To: PFIZER INC.

Reel/Frame 063119/0087 →

Continuity (3)

Provisional Application 61607485 · Mar 6, 2012

Provisional Application 61759307 · Jan 31, 2013

Related Publication 20130252961A1 · Sep 26, 2013